<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhou X</submitter><funding>Arizona State University/Mayo Clinic Collaborative Research Seed Grant</funding><funding>Mayo Clinic</funding><funding>NIGMS NIH HHS</funding><funding>National Institute of General Medical Sciences of National Institute of Health</funding><pagination>e05207</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12376538</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(31)</volume><pubmed_abstract>Single-molecule immunoassay is a reliable technique for the detection and quantification of low-abundance blood biomarkers, which are essential for early disease diagnosis and biomedical research. However, current single-molecule methods predominantly rely on endpoint detection and necessitate signal amplification via labeling, which brings a variety of unwanted effects, like matrix effect and autofluorescence interference. This study introduces a real-time mass imaging-based label-free single-molecule immunoassay (LFSMiA). Featuring plasmonic scattering microscopy-based mass imaging, a 2-step sandwich assay format enables background reduction, minimization of matrix effect by dynamic tracking of single binding events, and fully leveraging real-time data for improved measurement precision through a Bayesian Gaussian process model, the LFSMiA enables ultra-sensitive and direct protein detection at the single-molecule level in neat blood sample matrices. LFSMiA measurement is demonstrated for interleukin-6 and prostate-specific antigen in buffer, undiluted serum, and whole blood with sub-femtomolar detection limits and eight logs of dynamic ranges. Moreover, comparable performance is achieved with an inexpensive miniaturized setup. To show its translational potential to clinical settings and point-of-care diagnostics, N-terminal pro-B-type natriuretic peptide is examined in patient whole blood samples using the LFSMiA and results in a strong linear correlation (r > 0.99) with standard clinical lab results.</pubmed_abstract><journal>Advanced science (Weinheim, Baden-Wurttemberg, Germany)</journal><pubmed_title>Label-Free Single-Molecule Immunoassay.</pubmed_title><pmcid>PMC12376538</pmcid><funding_grant_id>ARI-285360-01</funding_grant_id><funding_grant_id>SPA00007255/ARI-333334</funding_grant_id><funding_grant_id>R01GM140193</funding_grant_id><funding_grant_id>R01 GM140193</funding_grant_id><pubmed_authors>Jiang J</pubmed_authors><pubmed_authors>Snozek CLH</pubmed_authors><pubmed_authors>Zhou S</pubmed_authors><pubmed_authors>Wang S</pubmed_authors><pubmed_authors>Wan Z</pubmed_authors><pubmed_authors>Braswell B</pubmed_authors><pubmed_authors>Chen C</pubmed_authors><pubmed_authors>Yang EH</pubmed_authors><pubmed_authors>Zhou X</pubmed_authors><pubmed_authors>Chemerkouh MJHN</pubmed_authors><pubmed_authors>Ma G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Label-Free Single-Molecule Immunoassay.</name><description>Single-molecule immunoassay is a reliable technique for the detection and quantification of low-abundance blood biomarkers, which are essential for early disease diagnosis and biomedical research. However, current single-molecule methods predominantly rely on endpoint detection and necessitate signal amplification via labeling, which brings a variety of unwanted effects, like matrix effect and autofluorescence interference. This study introduces a real-time mass imaging-based label-free single-molecule immunoassay (LFSMiA). Featuring plasmonic scattering microscopy-based mass imaging, a 2-step sandwich assay format enables background reduction, minimization of matrix effect by dynamic tracking of single binding events, and fully leveraging real-time data for improved measurement precision through a Bayesian Gaussian process model, the LFSMiA enables ultra-sensitive and direct protein detection at the single-molecule level in neat blood sample matrices. LFSMiA measurement is demonstrated for interleukin-6 and prostate-specific antigen in buffer, undiluted serum, and whole blood with sub-femtomolar detection limits and eight logs of dynamic ranges. Moreover, comparable performance is achieved with an inexpensive miniaturized setup. To show its translational potential to clinical settings and point-of-care diagnostics, N-terminal pro-B-type natriuretic peptide is examined in patient whole blood samples using the LFSMiA and results in a strong linear correlation (r > 0.99) with standard clinical lab results.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Aug</publication><modification>2026-05-09T17:50:58.898Z</modification><creation>2026-04-08T01:08:50.981Z</creation></dates><accession>S-EPMC12376538</accession><cross_references><pubmed>40538199</pubmed><doi>10.1002/advs.202505207</doi></cross_references></HashMap>